NATURE:中性粒细胞可护送循环肿瘤细胞

2019-02-10 海北 MedSci原创

研究人员认为,更好地理解和定义癌细胞和免疫细胞之间相互作用的特征对于新癌症疗法的开发是至关重要的。

研究人员认为,更好地理解和定义癌细胞和免疫细胞之间相互作用的特征对于新癌症疗法的开发是至关重要的。然而,现有研究的焦点通常是在原发肿瘤及其微环境中发生的相互作用,而在患者中,免疫细胞在癌症传播期间的作用仍然很大程度上没有被表征。

循环肿瘤细胞(CTC)是几种类型的癌症转移的前体,并且偶尔在血流中与非恶性细胞,如白细胞(WBC),相关联。目前为止,这些CTC相关WBC的特性和功能,以及定义WBCCTC之间相互作用的分子特征尚不清楚。

最近,研究人员分离和表征了来自乳腺癌患者和小鼠模型的个体CTC相关的WBC,以及每个CTC-WBC簇内的相应癌细胞。

研究人员使用单细胞RNA测序发现,在大多数病例中,CTC与中性粒细胞相关。当比较与中性粒细胞相关的CTC的转录组谱与单独的CTC的转录组谱时,研究人员检测到了许多差异表达的基因,这些基因勾勒出细胞周期进展,导致更有效的转移形成。

此外,研究人员确定了定义CTC-中性粒细胞簇的细胞-细胞连接和细胞因子-受体关系,其代表转移过程的关键脆弱性。

因此,嗜中性粒细胞和CTC之间的关联驱动血流中的细胞周期进展,并扩展了CTC的转移潜力,这提供了在乳腺癌治疗中靶向这种相互作用的基本原理。


原始出处:

Barbara Maria Szczerba et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 2019; doi: 10.1038/s41586-019-0915-y.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883584, encodeId=689b1883584fc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 16 08:05:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296694, encodeId=1624129669416, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313028, encodeId=c302131302878, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580973, encodeId=adb915809e3e0, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-10-16 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883584, encodeId=689b1883584fc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 16 08:05:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296694, encodeId=1624129669416, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313028, encodeId=c302131302878, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580973, encodeId=adb915809e3e0, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883584, encodeId=689b1883584fc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 16 08:05:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296694, encodeId=1624129669416, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313028, encodeId=c302131302878, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580973, encodeId=adb915809e3e0, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883584, encodeId=689b1883584fc, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 16 08:05:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296694, encodeId=1624129669416, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313028, encodeId=c302131302878, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580973, encodeId=adb915809e3e0, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Tue Feb 12 05:05:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]

相关资讯

2018年中国肿瘤临床试验蓝皮书

1. 前言 本蓝皮书纳入统计的肿瘤试验全部来源于“药物临床试验登记与信息公示平台”(http://www.chinadrugtrials.org.cn/eap/main),时间以登记网站上“首次公示信息日期”作为统计时间节点,有些试验可能早就结束,但首次公示信息日期是2018年,也纳入统计;有些试验招募的是健康受试者,则不在统计范围以内。 2.

抗肿瘤药物常“伤心”,该怎么防?

心血管疾病和肿瘤是威胁人类健康的两大杀手,肿瘤合并心血管疾病在临床中十分常见。与此同时,随着肿瘤诊治水平的提升,肿瘤患者生存率、生存时间不断改善,抗肿瘤治疗引起的心血管毒性也逐渐受到关注,成为影响肿瘤患者生活质量和预后的重要因素,为解决相关问题,肿瘤心脏病学作为一门新兴学科随即出现,并发挥着越来越重要的作用。

中年女性,右髋部肿瘤,请诊断!

患者2年前因左髋骨折摄片时偶然发现右髋部肿瘤,患者定期检测右髋部情况。1月前,患者右髋出现隐痛,能忍受,左髋亦有痛疼感。

Lancet oncol:Tisotumab vedotin可安全治疗多种固体肿瘤

Tisotumab vedotin是一种针对在多种实体肿瘤中均有表达、与临床预后差相关的组织因子的首个人体内的抗体-药物偶联物。现研究人员在表达组织因子的局部晚期或转移性固体肿瘤患者的混合人群中评估tisotumab vedotin的安全性、耐受性、药代动力学和抗肿瘤活性。研究人员在USA和欧洲的21个中心开展一个I-II期的开放性、剂量递增性和剂量扩展性研究(InovaTV201),招募年满18

开年大吉:张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变:肿瘤学I期临床试验年度报告》

长期以来,冗长的药品审评流程导致很多新药在中国大陆迟迟无法上市,患者面临无药可用的困境,这一现象在业内被称为“药滞(Drug-lag)”。2017年以来,国家实施了一系列药品审评、监管制度改革,旨在彻底扭转这一困局。近年来,抗肿瘤药物研发模式也发生了巨大变革,“无缝(seamless)设计”逐渐取代传统的三阶段药物开发模式。I期临床试验从原来的安全性试验转变为机制验证性(proof-of-mech